Actively Recruiting
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
Led by Revolution Medicines, Inc. · Updated on 2026-05-01
500
Participants Needed
17
Research Sites
238 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard of care (SOC) observation only.
CONDITIONS
Official Title
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- At least 18 years old and has provided informed consent
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Histologically confirmed pancreatic ductal adenocarcinoma (PDAC) with complete surgical removal (R0/R1) and no signs of recurrence or metastasis
- Received perioperative multi-agent chemotherapy (neoadjuvant, adjuvant, or both)
- Completed most recent chemotherapy treatment within the past 12 weeks
- Adequate bone marrow, liver, kidney, and coagulation function
- Documented RAS mutation status
- Able to take oral medications
You will not qualify if you...
- Prior treatment with direct RAS-targeted therapies such as degraders or inhibitors
- Any condition affecting ability to take or absorb the study drug
- Major surgery within 28 days before randomization
- Inability or unwillingness to comply with study visits or procedures
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 17 locations
1
University of California, Los Angeles
Los Angeles, California, United States, 90404
Actively Recruiting
2
University of California, San Francisco
San Francisco, California, United States, 94143
Not Yet Recruiting
3
Hartford Healthcare
Hartford, Connecticut, United States, 06103
Actively Recruiting
4
Community Health Network
Indianapolis, Indiana, United States, 46250
Actively Recruiting
5
University of Kansas Medical Center Research Institute, Inc.
Lawrence, Kansas, United States, 66045
Actively Recruiting
6
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins
Baltimore, Maryland, United States, 21287
Actively Recruiting
7
Saint Luke's Cancer Institute
Kansas City, Missouri, United States, 64111
Actively Recruiting
8
Columbia University Medical Center
New York, New York, United States, 10032
Actively Recruiting
9
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065
Actively Recruiting
10
Taylor Cancer Research Center
Maumee, Ohio, United States, 43537
Actively Recruiting
11
Avera Cancer Institute
Sioux Falls, South Dakota, United States, 57105
Actively Recruiting
12
University of Utah, Huntsman Cancer Institute
Salt Lake City, Utah, United States, 94112
Actively Recruiting
13
Virginia Cancer Specialists
Fairfax, Virginia, United States, 22031
Actively Recruiting
14
Pan American Oncology Trials, LLC
San Juan, Puerto Rico, Puerto Rico, 00909
Actively Recruiting
15
University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Medical Centre
Birmingham, United Kingdom, B15 2TH
Actively Recruiting
16
The Royal Marsden NHS Foundation Trust, Royal Marsden Hospital-London
London, United Kingdom, SW3 6JJ
Actively Recruiting
17
Imperial College Healthcare NHS Foundation Trust, Hammersmith Hospital
London, United Kingdom, W12 0HS
Actively Recruiting
Research Team
R
Revolution Medicines Study Director
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here